Research |
![]() ![]() ![]() ![]() ![]() |
Serial Number | 79352300 |
Mark Drawing Code | 4000: Illustration: Drawing with word(s)/letter(s)/number(s) in Block form |
2022-08-01 | Application Filed |
2022-10-13 | Location: INITIAL REVIEW/SERIALIZATION BRANCH(MAILROOM) |
2022-10-13 | Status: Live/Pending |
2022-10-14 | Transaction Date |
Owner: | ![]() |
Address | Science Park 408 NL-1098 XH AMSTERDAM NL |
Legal Entity Type | Besloten Vennootschap (b.v.) |
Legal Entity State | NL |
Click the blue "Refresh" button to load certificates, specimines, application, and other documents.
International Codes: | 5 |
U.S. Codes: | 005,006,018,044,046,051,052 |
International Codes: | 42 |
U.S. Codes: | 100,101 |
International Codes: | 44 |
U.S. Codes: | 100,101 |
Type Code | Type |
---|---|
GS0051 | Viral systems, gene therapy systems, nucleic acid delivery systems, namely, viral vectors, non-viral vectors, gene therapy vectors, nucleic acid delivery vectors, and cells transformed by viral vectors, non-viral vectors, gene therapy vectors or nucleic acid delivery vectors for medical purposes; pharmaceutical products; biological preparations for use in medical and clinical gene therapy, nucleic acid-based therapy and cell therapy; clinical medical reagents for use in nucleic acid-based therapy, gene therapy, cell therapy, gene diagnosis and gene testing; pharmaceutical preparations, vaccines, prophylaxis products and other pharmaceutical products for use in nucleic acid-based therapy, gene therapy and cell therapy |
GS0051 | Viral systems comprised of viral vectors combined with antibodies; gene therapy systems comprised of viral vectors combined with antibodies; nucleic acid delivery systems being therapeutic agents for delivery to human tissue namely viral vectors, non-viral vectors, gene therapy vectors, nucleic acid delivery vectors, and cells transformed by viral vectors, non-viral vectors, gene therapy vectors or nucleic acid delivery vectors for medical purposes; pharmaceutical products for the treatment of neuro degenerative and neuromuscular disorders being autoimmune diseases; biological preparations for the treatment neuro degenerative and neuromuscular disorders being autoimmune diseases; biological preparations for use in medical and clinical gene therapy, nucleic acid-based therapy and cell therapy for the treatment of neuro degenerative and neuromuscular disorders being autoimmune diseases; clinical medical reagents for use in nucleic acid-based therapy, cell therapy, pharmaceutical preparations, prophylaxis products preparations and other pharmaceutical products preparations and other pharmaceutical products preparations for use in nucleic acid-based therapy, gene therapy for the treatment of neuro degenerative and neuromuscular disorders being autoimmune diseases |
Description | Date | Event Coding |
---|---|---|
SN ASSIGNED FOR SECT 66A APPL FROM IB | 2022-10-13 | 1 REPR M: |
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM | 2022-10-14 | 2 NWOS I:Incoming Correspondence |
APPLICATION FILING RECEIPT MAILED | 2022-10-18 | 3 MAFR O:Outgoing Correspondence |
NEW REPRESENTATIVE AT IB RECEIVED | 2023-04-11 | 4 NREP P: |
ASSIGNED TO EXAMINER | 2023-05-18 | 5 DOCK D:Assigned to Examiner |
NON-FINAL ACTION WRITTEN | 2023-05-19 | 6 CNRT R:Renewal |
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | 2023-05-20 | 7 RFCR E:E-Mail |
REFUSAL PROCESSED BY MPU | 2023-06-27 | 8 RFRR P: |
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | 2023-06-27 | 9 RFCS P: |
REFUSAL PROCESSED BY IB | 2023-07-22 | 10 RFNT P: |
TEAS RESPONSE TO OFFICE ACTION RECEIVED | 2023-12-07 | 11 TROA I:Incoming Correspondence |
CORRESPONDENCE RECEIVED IN LAW OFFICE | 2023-12-07 | 12 CRFA I:Incoming Correspondence |
TEAS/EMAIL CORRESPONDENCE ENTERED | 2023-12-08 | 13 TEME I:Incoming Correspondence |
EXAMINERS AMENDMENT -WRITTEN | 2023-12-12 | 14 CNEA R:Renewal |
EXAMINERS AMENDMENT E-MAILED | 2023-12-12 | 15 GNEA O:Outgoing Correspondence |
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | 2023-12-12 | 16 GNEN O:Outgoing Correspondence |
EXAMINER'S AMENDMENT ENTERED | 2023-12-12 | 17 XAEC I:Incoming Correspondence |
APPROVED FOR PUB - PRINCIPAL REGISTER | 2023-12-18 | 18 CNSA O:Outgoing Correspondence |
WITHDRAWN FROM PUB - OG REVIEW QUERY | 2024-01-02 | 19 PBCR Z:Deletion |
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | 2024-01-31 | 20 NPUB E:E-Mail |
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | 2024-01-31 | 21 NONP E:E-Mail |
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | 2024-02-07 | 22 OP2R P: |
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | 2024-02-07 | 23 OPNS P: |
PUBLISHED FOR OPPOSITION | 2024-02-20 | 24 PUBO A:Allowance for Publication |
NOTIFICATION PROCESSED BY IB | 2024-02-26 | 25 GPNX P: |
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | 2024-03-04 | 26 NPUB E:E-Mail |
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | 2024-03-13 | 27 OPNR P: |
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | 2024-03-13 | 28 OPNS P: |
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | 2024-04-01 | 29 OPNX P: |
REGISTERED-PRINCIPAL REGISTER | 2024-05-07 | 30 R.PR A:Allowance for Publication |
NOTICE OF REGISTRATION CONFIRMATION EMAILED | 2024-05-07 | 31 NRCC E:E-Mail |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.